Fundamental Analysis of TONIX PHARMACEUTICALS HOLDIN(NASDAQ:TNXP) stock

Fundamental Rating

Overall TNXP gets a fundamental rating of 2 out of 10. We evaluated TNXP against 565 industry peers in the Biotechnology industry. Both the profitability and financial health of TNXP have multiple concerns. TNXP is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TNXP has reported negative net income.

In the past year TNXP has reported a negative cash flow from operations.

TNXP had negative earnings in each of the past 5 years.

In the past 5 years TNXP always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of TNXP (-211.95%) is worse than 91.27% of its industry peers.

Looking at the Return On Equity, with a value of -353.93%, TNXP is doing worse than 76.65% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-211.95%
ROE	-353.93%
ROIC	N/A

ROA(3y)-55.21%

ROA(5y)-86.34%

ROE(3y)-69.72%

ROE(5y)-119.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of TNXP (21.63%) is better than 75.22% of its industry peers.

TNXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	21.63%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.

TNXP has less shares outstanding than it did 1 year ago.

TNXP has more shares outstanding than it did 5 years ago.

The debt/assets ratio for TNXP is higher compared to a year ago.

2.2 Solvency

TNXP has an Altman-Z score of -17.34. This is a bad value and indicates that TNXP is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -17.34, TNXP is doing worse than 83.96% of the companies in the same industry.

TNXP has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.

TNXP's Debt to Equity ratio of 0.13 is on the low side compared to the rest of the industry. TNXP is outperformed by 65.95% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Altman-Z	-17.34

ROIC/WACCN/A

WACC10.2%

2.3 Liquidity

TNXP has a Current Ratio of 1.15. This is a normal value and indicates that TNXP is financially healthy and should not expect problems in meeting its short term obligations.

TNXP has a worse Current ratio (1.15) than 85.20% of its industry peers.

A Quick Ratio of 0.72 indicates that TNXP may have some problems paying its short term obligations.

With a Quick ratio value of 0.72, TNXP is not doing good in the industry: 90.55% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.15
Quick Ratio	0.72

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TNXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.73%, which is quite impressive.

EPS 1Y (TTM)74.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%77.52%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TNXP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.92% on average per year.

Based on estimates for the next years, TNXP will show a very strong growth in Revenue. The Revenue will grow by 74.72% on average per year.

EPS Next Y94.68%

EPS Next 2Y37.32%

EPS Next 3Y25.92%

EPS Next 5YN/A

Revenue Next Year61.45%

Revenue Next 2Y42.72%

Revenue Next 3Y74.72%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TNXP's earnings are expected to grow with 25.92% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.32%

EPS Next 3Y25.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TNXP does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (11/21/2024, 1:02:08 PM)

0.2063

+0.02 (+8.58%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap36.84M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-211.95%
ROE	-353.93%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	21.63%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.18

Health

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.15
Quick Ratio	0.72
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)74.73%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y94.68%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TONIX PHARMACEUTICALS HOLDIN (TNXP)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens